International Conference on AIDS by Dabis, F. et al.
MEE 'INC REPOR 
Estimating the rate of mother-to-child transmission of HIV. 
Report of a workshop on methodological issues 
Chent (Belgium), 17-20 February 1992 
Francois Dabis, Philippe Msellati, David Dunn*, Philippe Lepage?, 
Marie-Louise Newell*, Catherine Peckham*, Philippe Van de Perre1 
and the Working Group on Mother-to-Child Transmission of HIVg 
Purpose: In the last 8 years, numerous cohort studies have been conducted to estimate 
the rate of mother-to-child transmission (MTCT) of HIV. Many of these have faced 
problems in data collection and analysis, making it difficult to compare transmission 
rates between studies. This workshop on methodological aspects of the study of MTCT 
of HIV-1 was held in Chent (Belgium) in February 1992. 
Study selection and data extraction: Fourteen teams of investigators participated, 
representing studies from Central (five) and Eastern Africa (three), Europe (two), Haiti 
(one) and the United States (three). A critical evaluation of the projects was carried out, 
under four headings: (1) enrollment and follow-up procedures, (2) diagnostic criteria and 
case defini$ons, (3) measurement and comparison of MTCT rates and (4) determinants 
of transmission. 
Results of data analysis: Reported transmission rates ranged from 13 to 32% in 
industrialized countries and from 25 to 48% in developing countries. However, no 
direct comparisons could be made because methods of calculation differed from study 
to study. Based on this review, a common methodology was developed. Agreement was 
reached on definitions of HIV-related signs/symptoms, paediatric AIDS and HIV-related 
deaths. A classification system of children born to HIV-I-infected mothers according 
to their probable HIV infection status during the first 15 months of life, allowed 
the elaboration of a direct method of computation of the transmission rate and 
of an indirect method for studies with a comparison group of children born to 
HIV-seronegative mothers. This standardized approach was subsequently applied to 
selected data sets. 
Conclusions: The methodology can now be applied to all studies with sufficient 
follow-up and comparisons made between transmission rates. This step is essential 
for assessing determinants of transmission and for the development of a common 
approach for the evaluation of interventions aimed at reducing or interrupting MTCT 
of HIV. 
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Introduction 
The worldwide spread of HIV through heterosexual 
contacts and intravenous drug use has lead to a high 
prevalence of infection among women of child-bear- 
ing age, particularly in Africa [ 11% Mother-to-child trans- 
mission (MTCT) of HIV, often referred to as perina- 
tal transmission, is a direct consequence of this epi- 
demiological pattern. The World Health Organization 
(WHO) estimates that by 1992, almost 1 million in- 
fected children had been born to HIV-infected moth- 
ers since the beginning of the HN epidemic. Almost 
half a million have already developed AIDS and subse- 
quently died [ 21, A larger number of uninfected chil- 
dren are likely to become orphans because of the loss 
of one or both parents from HIV disease [1,3]. 
Many researchers have been engaged in the study of 
MTCT of HIV since the mid-1980s [4-71. These studies 
are necessary for at least five reasons: (1) to estimate 
the MTCT rate of HIV for demographic projections 
[ 1,2] ; (2) for planning health resources allocation; (3) 
to obtain a reliable range of values for MTCT of HIV 
and to compare rates of transmission in various set- 
tings; (4) to understand the determinants of MTCT of 
HIV so that factors amenable to interventions which 
could decrease transmission can be identified; (5) to 
improve individual counselling and the case manage- 
ment of mothers and children. 
Investigators of MTCT studies confront many practi- 
cal problems, including dficulties with survey instru- 
ments, definitions used for calculating the rate of trans- 
mission and the protocol of clinical and biological 
follow-up of children. The need for a methodologi- 
cal workshop on MTCT of HlV with special refer- 
ence to Africa was recognized by several investiga- 
tors, the European Economic Community (EEC) AIDS 
Task Force and WHO in 1988 [SI. Most of the ongo- 
ing studies had insufficient follow-up at that time to 
provide definite results for the formulation of recom- 
mendations for public health and clinical practice. 
A meeting was held in 1992 in Ghent (Belgium) under 
the auspices of the EEC AIDS Task Force, in collabo- 
ration with the WHO Global Programme on AIDS and 
UNICEF. This workshop included 40 scientists from 
three continents who were experts in paediatrics, ob- 
stetrics, virology, epidemiology and biostatistics. The 
objectives were: (1) to address methodological is- 
sues in the estimation of the rate of MTCT of HIV-1 
with special reference to developing countries; (2) to 
present a critical evaluation of selected perinatal stud- 
ies using a standardized methodological approach. 
This report provides a summary of the discussions 
and recommendations made during the workshop for 
further analysis and follow-up of ongoing studies and 
for the direction and design of future studies. 
Overview of the completed and ongoing 
studies h 
The principal investigators of 14 studies participated 
in this workshop. Five reviewed studies were from 
Central Africa [$-14], three from Southern and East- 
ern Africa [15-171, one from the Caribbean [181, 
three from the USA [19-221 and two from Europe 
[ 23-25]. With the exception of one study in Central 
Africa [ 131, these were based in large urban centres 
where HIV seroprevalence is high. In developing coun- 
tries, there was a wide range in seroprevalence among 
pregnant women screened, from 3.996 in Brazzaville 
(Congo) in 1987-1989 [lo] to 30% in Kigali (Rwanda) 
in 1988-1989 [ 113, Few seroprevalence figures were 
available for industrialized countries. 
AU studies reviewed included as an objective the meas- 
urement of the rate of HIV MTCT and the description 
of the natural history of paediatric HIV infection. How- 
ever, only about half were able to collect data on po- 
tential determinants of HlV MTCT. All studies started 
between 1985 and 1989. The availability of early dia- 
gnostic tools was limited at the start and varied ac- 
cording to site, influencing the design of these studies. 
Eight studies enrolled livebirths and six enrolled preg- 
nant women, either during pregnancy or at delivery. 
Enrollment took place in prenatal clinics or maternity 
wards. 
The number of children born to HIV-seropositive 
mothers enrolled in each study varied from 112 to 
1060 in industrialized countries and from 118 to 679 
in developing countries. Only two studies from in- 
dustrialized countries included a comparison group 
[21,22], compared with the nine studies in devel- 
oping countries. Various criteria were used to select 
the comparison group (next delivery, age, parity, ge- 
ographical origin, etc.). The number of children born 
to HIV-seronegative mothers enrolled in the compar- 
ison group varied from 40 to 3589 per study. Formal 
sample size calculation was rarely performed before 
the study was started. 
In all studies, there was a regular clinical follow-up 
throughout the first year of life but there was more 
variation in the timing and frequency of blood sam- 
pling and in the overall length of follow-up. In most 
studies, mortality in the comparison group (children 
born to HIV-seronegative mothers) was lower than 
anticipated, due to surveillance bias. The different es- 
timations of the rate of HIV MTCT reported ranged 
from 13 to ,3296 in industrialized countries and from 
26 to 48% in developing countries (Fig. 1). However, 
in each study, the method used to estimate the MTCT 
rate of HIV was study-specific. 
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Fig. I. Reported rates of mother-to-child transmission of HIV-1 
W o )  in five studies in industrialized countries (M) and in nine 
studies in developing countries (CI).  Chent, February 1992. 
Summary of recommendations 
Clinical and laboratory procedures 
Enrollment 
Women should be identified during pregnancy in pref- 
erence tÔ delivery to study the timing of transmission 
and all children enrolled at birth. A strict enrollment 
definition with clear inclusion criteria should be es- 
’ tablished and all enrolled children described in any 
publication. Strictly defined exclusion criteria should 
be used to reduce the loss to follow-up. Women re- 
’ fusing to participate in the study should be excluded, 
either at the initial enrollment or if they are unwill- 
ing to attend the first follow-up. In addition, it may 
be appropriate to exclude women and children not 
permanently resident in the catchment area. Children 
should be excluded if their mother was not tested at 
or before the time of delivery. Stillbirths should always 
be excluded from the calculation of the rate of HIV 
MTCT. 
No specifìc recommendation with regard to sample 
size could be made because the sample size depends 
on study-specific objectives. A comparison group is 
necessary for the calculation of excess mortality of 
children born to HIV-seropositive mothers (see Meas- 
urement and comparison of rates of transmission). Al- 
though it was recognized that the morbidity and mor- 
tality of the comparison group may not reflect that of 
the population from which it was derived, both co- 
horts have the same access to health care and special 
services provided by the study. It was recommended 
that the two groups should be made as comparable as 
possible in terms of maternal age and parity although 
individual matching was not considered essential. An- 
n. other justification for a comparison group is to identlfy 
maternal seroconversions and to study postnatal trans- 
mission [26], 
FOI10 W-Up 
Clinical information should aim to identify paedi- 
atric AIDS, HN-related signs/symptoms and HN-re- 
lated deaths (see proposed definitions in Diagnostic 
criteria and case definitions). Regular specimen col- 
lection (blood or other samples) up to at least 15 
months of life is important in the analysis of loss of 
maternal antibody. 
The estirnation of mortality should always use survival 
analysis methods (for example, Kaplan-Meier product 
limit method [27]). An effort should be made to es- 
tablish causes of death of children who died at home, 
using verbal autopsies [ 281. A standard verbal autopsy 
report should be used for this purpose. 
Loss to follow-up is a major problem in prospective 
studies and may bias the estimates of MTCT rates. 
It should be clearly defined and described. Where 
possible, comparisons should be made between the 
clinical and immunological characteristics of children 
lost to follow-up and those not lost to follow-up, in 
order to look for potential biases. 
Diagnostic criteria and case definitions 
Clinical assessment 
Two paediatric clinical AIDS definitions applicable to 
settings with scarce diagnostic facilities have been used 
in the past (Table 1): the WHO clinical definition 
[29] (the so-called Bangui definition) and a mod- 
ified version [8]. In the modified version, persistent 
cough is not included as a minor sign, but recurrent 
pneumonia is included as a major sign. These defini- 
tions have been evaluated cross-sectionally in various 
African countries using HIV-antibody test results as the 
gold standard [30-321. They have shown low sensi- 
tivity and positive predictive value. In cohort studies 
where repeated cross-sectional assessments are per- 
formed, the combination of signs and symptoms nec- 
essary to classify a child as fulfilling the AIDS criteria 
should be identified during the same observation pe- 
riod and not by cumulating morbidity experience over 
time. A comparative evaluation of the original WHO 
paediatric AIDS clinical definition and of the modified 
version should be performed within existing cohort 
studies. Meanwhile, the use of the original WHO case 
definition should be recommended. 
HIV-related signs and symptoms in children born to 
HIV-seropositive mothers 
It is often not possible to establish persistence of signs 
and symptoms in young infants. It is for this reason 
that a scoring system was developed in one study, to 
take into account the relative weight and the dynam- 
ics of the symptoms [9]. This scoring system needs 
to be evaluated against clinical AIDS definitions and 
new methods for early diagnosis of HTV infection 
before it is recommended for use in other research 
projects. Some signs and symptoms have been shown 
to be highly predictive of paediatric HIV infection. A 
list of HIV-related signs and symptoms is summarized 
in Table 2. 
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Table 1. World Health Organization case definitions for paediatric AIDS' 
used for the Chent classification of paediatric HIV infection, 1992. 
WHO clinical case definition for paediatric AIDS [291 
Major signs 
Weight loss or failure to thrive 
Chronic diarrhoea (>I month) 
Prolonged fever (> 1 month) 
Generalized lymphadenopathy 
Oro-pharyngeal candidiasis 
Repeated common infections 
Persistent cough 
Generalized dermatitis 
Confirmed maternal HIV infection 
Minor signs 
Modified WHO clinical case definition for paediatric AIDS I81 
Major signs 
Weight loss or failure to thrive 
Chronic diarrhoea (> 1 month) 
Prolonged fever (> 1 month) 
Severe or repeated pneumonia 
Generalized lymphadenopathy 
Oro-pharyngeal candidiasis 
Repeated common infections 
Generalized pruritic dematitis 
Confirmed maternal HIV infection 
Minor signs 
*With both definitions, paediatric AIDS is suspected in a child presenting 
with a least two major signs and two minor signs in the absence of known 
causes of immunosuppression. 
Table 2. HIV-related signs and symptoms in children born to HIV- 
seropositive mothers used for the Ghent classification of paediatric HIV 
infection, 1992. 
_ _ _ _ _ _ _ _ ~ ~ ~  ~~ ~ 
Persistent diarrhoea (2 15 days) 
Oral candidiasis (beyond the neonatal period) 
Generalized lymphadenopathy (enlarged lymph nodes in at least 
two independent anatomic sites) 
Failure to thrive (no weight gain for a period of 3 months 
or crossing two percentiles lines on the growth chart) 
Chronic parotitis (> 1 month) 
Herpes zoster infection ('shingles') 
Recurrent pneumonia (two or more episodes) 
HIV-related deaths in children born to HIV-seropositive 
mothers 
For the purpose of calculating the rate of HIV MTCT, it 
is important to establish whether a child who dies be- 
fore 15 months is HIV-infected. Three definitions were 
proposed for children who died before their infection 
status could be determined by serology (Table 3). 
Laboratory assessment 
A combination of HIV serum antibody enzyme-linked 
immunosorbent assay (ELISA) and Western blot (WB) 
tests was used in most cohort studies. A consensus was 
reached to assess WB according to the WHO criteria 
(positive WB if at least the gp41 and gp120/160 bands 
are reactive). More importantly, a negative WB should 
be dehed by the complete absence of any band. In- 
determinate WB consists of all other situations. Some 
Table 3. Definitions for children born to HIV-seropositive mothers who 
died before infection status could be determined by serology. Chent 
classification, 1992. 
Probable HIV-related death 
? Either AIDS' 
or 
At least one HIV-related sign/symptom** when last seen 
and 
Dying from severe infection? or persistent diarrhoea 
beyond the first 4 weeks of lifez 
Probable non-HlV-related death 
No HIV-related sign/symptoms** when last seen 
and 
Dying from cause other than severe infection? or 
persistent diarrhoea after the first 4 weeks of life 
Death with indeterminate relation to HIV infection 
AI1 deaths occurring within the first 4 weeks of life 
or 
Beyond this period, all the deaths not classified above 
'See definition in Table 1. **See definition in Table 2. tlt may be neces- 
sary to establish a list of severe paediatric infections for this purpose. 
$Children who died from persistent diarrhoea but do not present any 
other HIV-related sign/symptom should be considered as a death with 
indeterminate relation to HIV infection. 
.c 
I 8 
questions were raised about the necessity of using a 
confirmation test (WB) for longitudinal follow-up of 
children born to HIV-seropositive mothers [33]. Sim- 
pler and cheaper methods, such as two different types 
of ELISA, have been used in some MTCT studies. Dif- 
ferent diagnostic strategies should therefore be com- 
pared to WB on serum samples collected between 12 
and 18 months of age. 
There was a consensus to use 15 months of age as' 
the cut-off point for antibody loss for estimating MTCT 
rates. However, in infants lost to follow-up before 15 
months of age, a negative WB result obtained at or 
after 9 months could be considered as seroreversion 
in the absence of clinical AIDS. In the proposed defi- 
nition, such infants are categorized as uninfected with 
HIV. The group recognized that a small percentage'of 
HIV-infected infants transiently serorevert before again 
becoming HIV-seropositive [ 16,341. In most studies, 
the windows of seronegativity have occurred between 
3 and 8 months of age with a few exceptions. Omit- 
ting the small number of infants with longer windows 
should not have a significht impact on the overall es- 
timation of the MTCT rate. 
Various methods for the early diagnosis of H N  s e c -  
tion in infants born to HN-seropositive mothers were 
discussed [viral culture, polymerase chain reaction, 
p24 antigen, in vitro antibody production, HIV-specific 
serum immunoglobulin A (IgA)] [35]. It was agreed 
not to integrate any of these criteria in the proposed 
methods of estimation of the MTCT rate of HIV at the 
present time. However, the recommendations made at 
the Sienna meeting held in January 1992 on the early- 
diagnosis of HIV infection in infants, should be used 
by the Working Group in the future [36], These new 
t 
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diagnostic tools, particularly HIV-specific IgA antibody 
tests [37], should first be evaluated in available stored 
serum samples from existing studies. The confirmation 
of the diagnostic value of specific IgA antibody tests on 
large numbers of serum samples collected at G and 
3 9 months of age in children born to HIV-seropositive 
mothers and performed in a single laboratory facility 
was considered a research priority. It was felt that this 
result could be used to validate and revise the Ghent 
classification. 
Measurement and comparison of transmission rates 
General approach to the problem 
Ideally, the transmission rate (TR) for MTCT of HIV 
should be computed as: TR = number of HIV-infected 
childredtotal number of children enrolled. Based on 
the experience of the workshop participants, it was 
decided that calculations should be made using all the 
available information for the first 15 months of follow- 
up. In studies that do not have serum samples available 
at 15 months of age, the 12-month cut-off should be 
used. There are problems in estimating both the nu- 
merator (how to define an HIV-infected child?) and the 
denominator of this rate (how should deaths before 
15 months of age and losses to follow-up be consid- 
ered?). 
The definitions proposed in Tables 1 and 3 to clas- 
sify a child as HIV-infected can be recommended. A 
classification of children according to their probable 
'1 HN infection status was developed and is presented in 
Table 4 and Fig. 2. This classification should be used to 
compare cohort studies and to minimize the number 
of children whose H N  infection status remains inde- 
terminate. The risk of misclassification of HN-infected 
children was recognized. In some studies, several chil- 
dren who had seroreverted were shown later to have 
detectable HIV antibodies again [ 16,341. Before taking 
this into account in the present classification, detailed 
description of these sequential laboratory results, as 
well as- further laboratory testing using new diagnostic 
tools, were felt to be necessary in those studies report- 
'ing this phenomenon frequently. 
Methods for estimating the MTCT rate of HIV 
Several methods have been used to estimate the MTCT 
rate, including: (1) the use of antibody tests results 
only; (2) the use of antibody test results combined 
with an estimate of excess mortality observed in chil- 
dren born to HIV-seropositive mothers; (3) the use 
of antibody test results combined with a clinical as- 
sessment of HIV infection status in children without 
definitive serology (either because they died or were 
lost to follow-up); (4) the use of other virological 
and immunological methods. The latter will not be 
considered further in order to allow a standardized 
methodology to be applied to many of the studies 
A in developing countries without access to advanced 
virological testing. Also, quantitative antibody assays 
will not be considered [ 191 but all the antibody test 
Table 4. Ghent classification' of children born to HIV-seropositive mothers 
according to their probable HIV infection status, 1992. 
HIV-infected 
HIV WB-antibody positive at 15 months 
or 
HIV-related death (see definition in Table 3) 
or 
AIDS (see definition in Table 1) 
HIV-non-infected 
HIV WB-serum-antibody-negative at 15 months 
or 
HIV WB-negative 2 9 months in a child lost to 
or 
HIV WB negative 2 9 months in a child who died 
from probable non-HIV-related cause (see definition 
in Table 3) 
~OIIOW-UP without AIDS 
Indeterminate HIV infection status 
Death before 15 months with indeterminate relation 
to HIV infection (see definition in Table 3) 
Child died of probable not HIV-related cause while 
WB-positive or indeterminate before 15 months or 
WB-negative < 9 months (when last seen) 
or 
Child lost to follow-up while WB-positive or 
indeterminate before 15 months or WB-negative 
< 9 months (when last seen) 
or 
Child with indeterminate WB  and alive at 15 months 
Or 
*This classification is designed to be used in the estimation of the rate 
of mother-to-child transmission of HIV and the comparisons between 
studies and not in the management of children born to HIV-seropositive 
mothers. The use of this classification must be restricted to a cohort of 
children born to HIV- seropositive mothers, all of whom were born more 
than 15 months before analysis. All children of the cohort should be ac- 
counted for using the above classification. In those studies where other 
methods of diagnosis such as viral culture are used, the results of these 
methods should be described if modifying the classification, but should 
be ignored for the purpose of comparisons. WB, Western blot. 
results should be interpreted as negative, positive or 
indeterminate. 
In method 1, clinical information is not considered. 
Each child is defìned as infected (WB-positive after 15 
months), uninfected (WB-negative after 9 months) or 
indeterminate (otherwise). The number of children in 
these three categories is denoted as n +  , n- and n?, 
respectively. The total size of the cohort of children 
born to HIV-seropositive mothers is denoted as N. 
There are three possible ways to estimate the transmis- 
sion rate (TR). The lower estimate assumes that all  in- 
determinates are uninfected: TR = n+/N. The upper 
estimate assumes that all indeterminates are infected: 
TR = (n+ ) 4- (n?)/N. The intermediate estimate as- 
sumes that indeterminates provide no information on 
HIV infection status: TR = (n-t)/(n-t) -I- (n-). This 
first method will yield an unacceptably wide range be- 
tween the lower and upper estimates if a study has a 
high background or HIV-specific infant mortality rate 
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Children bom to 
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2 15 months 
r-4 Indeterminat 
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HIV-related 
23 Infected 
Y 
Fig. 2. Algorithm used to classify children born to HIV-seropositive mothers according to their probable HIV infection status. Ghent i' 
classification, 1992. *See definition in Table 1; **see definition in Table 3. WB, Western blot. 
or a high rate of loss to follow-up. In these circum- 
stances, the number of indeterminate children will be 
very high. Consequently, the use of method 1 is not 
recommended since most of the studies considered 
suffer from either or both of these problems. 
Method 2 requires a comparison group of children 
born to HIV-seronegative mothers. It will be referred 
to as the indirect method. There is no need to make 
a clinical assessment of HIV infection with this ap- 
proach. It addresses a weakness of method 1, namely 
that infected children of HIV-seropositive mothers, the 
exposed group, may be more likely to die before 15 
months than uninfected children of HIV-seropositive 
mothers. TO avoid having to determine whether the 
death was HIV-related, the comparison - unexposed 
- group is used to model the mortality experience 
of uninfected children of HIV-seropositive mothers. 
The indirect method is applicable to settings with a 
comparison group of at least the same size and simi- 
lar socio-economic conditions as the exposed group. 
Let m o  (ml) denote the probability of dying be- 
fore 15 months for children bom to HIV-seronega- 
tive (seropositive) mothers; these probabilities should 
be estimated using survival analysis methods, regard- 
ing loss to follow-up as a censoring event [27]. If 12 
rather than 15 months is used to deíine definitive serol- 
ogy, then the probabilities of dying before 12 months 
should be calculated instead. The excess mortality is 
computed as: (ml - mo). Let p denote the propor- 
tion of children who are HIV-antibody-positive at 15 
months (or 12 months when appropriate). The stan- 
dard way of estimating the TR by this formula has been 
[MI: TR = (ml - mo) -I- p, with p estimating the pro- 
portion of HN-antibody-positive children in the entire 
cohort, which includes children who died because of 
HIV infection. However, this effectively counts children 
who died as a consequence of HIV infection twice. An 
attempt was made to improve on this method by ap- 
plying the prevalence of antibody carriage to the total 
number of children in the cohort minus the estimated 
number of children who died of causes related to HIV 
infection. Thus, the preceding formula should be mod- 
ified as follows: 
T R =  ml - mo -t (p x (1 - ml)) 
1 - mO 
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This indirect method does not resolve the problem 
that loss to follow-up may be related to HIV infection 
status but lost to follow-up is taken into account in the 
computation of probabilities of dying in both groups. 
A key assumption for this method is that uninfected 
3 children of HIV-infected mothers have the same mor- 
tality experience as children of uninfected mothers. It 
is very likely that maternal HIV infection per se may 
have an adverse effect on the mortality of a child. 
Consequently, the excess mortality and thus the MTCT 
rate of HIV could be overestimated with the indirect 
method, although the extent of this bias is difficult to 
quantify. The 95% confidence interval (CI) of TR ob- 
tained with the indirect method can be calculated as: 
TR f 1.96 X ,/-The variance of the trans- 
mission rate, Var (TR), can be calculated as (details are 
available upon request): 
vars1 + vars0 
Sl2 so2 
SO and S1 are the probabilities of surviving in both 
groups computed by survival techniques, with their 
variance usually computed by Rothman’s formula [ 381. 
SR is the survival ratio: SR = S1/ SO = (1 - ml)/(l - 
mo). Other information required is: n, the denomina- 
tor upon which the rate of seropositivity (p) is based, 
i.e., the number of children born to HIV-seropositive 
mothers and surviving at 15 months of age. 
Method 3 uses the classification of children born to 
HIV-seropositive mothers according to their probable 
i HIV infection status (Table 4 and Fig. 2). Method 3 will 
be referred to as the direct method. The three formu- 
las under method 1 can be applied, with n+ denoting 
HIV-infected children, n-denoting HIV-uninfected chil- 
dren and n? denoting children with indeterminate HIV 
infection status. The success of this method depends 
on the accuracy of clinical assessment. As most early 
deaths or early losses to follow-up will be classified 
as indeterminate HIV infection status, this method will 
yield disparate lower and upper estimates if there are 
substantial numbers of such children. The 95% CI of 
TR obtained with the direct method is easily calculated 
with the standard methods for proportions: 
95%CI(TR) = TR f 1.96 X J” (: - 
TR is the transmission rate, ranging between O and 1; 
D is the denominator used for its computation, N or 
(n+ ) + (n-) depending of the formula used to cal- 
culate TR. 
Application of the methods of calculation of the 
transmission rate 
The data collected in Kigali (Rwanda) between 1988 
and 1990 during an ongoing MTCT study [12] were 
used to illustrate the use of the three methods previ- 
ously described. In this cohort, 218 (N) children born 
to HIV-seropositive mothers and 218 children born to 
HIV-seronegative mothers were followed from birth. 
In the group of children born to HIV seropositive 
mothers, 27 were alive and HIV-antibody-positive at 
15 months (ni- ). At that time, 136 were alive and HIV- 
antibody-negative (n-). Seven had been lost to follow- 
up between 9 and 15 months, at a time when theywere 
already HIV-antibody-negative. The remaining 48 chil- 
dren could not be classified as HN-antibody-positive 
or negative at 15 months because of early death in 31 
or loss to follow-up in 17. 
Using method 1, the minimum value was: TR = 27/218 
= 12.4% (CI = 8.0-16.8%). The maximum value was 
TR = (27 + 48)/218 = 34.4% (CI = 28.140.7%) and 
theintermediatevaluewasTR = 27/(27 + 136) = 16.6% 
(CI = 10.9-22.3%). This shows clearly why the use of 
method 1 cannot be recommended in a context where 
the number of indeterminate children is high (48 chil- 
dren or 22% of the cohort). 
To use the indirect method (method 2), the following 
information was obtained using Kaplan-Meier tech- 
niques: ml = 0.1462, mO = 0.0416 and the excess 
of mortality, ml-mO = 0.1046. The number of chil- 
dren alive at 15 months of age was 174 (nl) in the 
cohort of children born to HIV-seropositive mothers 
and 201 (no) in the comparison group. An estimate 
of TR can be obtained with the indirect method, 
using as the prevalence of antibody at 15 months 
(p), the intermediate value of TR obtained with 
method 1: p = 27/(27 + 136) = 0.1656. The estimate 
of TR is therefore TR = 25.7% (CI = 18.8-32.5%). The 
95% CI of TR is obtained by computing Var (TR) 
with the following figures: n = 163, S1 = 0.8539, Var 
S1 = 0.00059, So = 0.9584 and Var So = 0.00018. 
The use of Ghent classification (method 3) for the 218 
children born to HIV-seropositive mothers in Kigali 
gave the following three groups: 46 HIV-infected chil- 
dren, 140 non-HN-infected and 32 with indeterminate 
HIV infection status. For the definition of HIV-infected 
children, the 1989 revision of the WHOclinical def- 
inition of paediatric AIDS [8] rather than the 1986 
Bangui definition was used. Of the 46 children clas- 
sified as HIV-infected, 16 were AIDS cases regardless 
of their HIV serological status (seven of those subse- 
quently died before 15 months of age); 23 were alive, 
followed up to 15 months and WB-positive at that 
time; finally, eight died of HIV-related causes before 
15 months of age. For the uninfected group, 135 were 
negative at 15 months and five were lost to follow-up 
before but were WB-negative at or after 9 months. 
Thus, the use of the direct method gave the follow- 
ing three estimates of TR: .a minimum estimate of 
46/218 = 21.1% (CI = 15.7-26.5%), a maximum es- 
timate of (46 + 32)/218 = 35.8% (CI = 29.4-42.1%) 
and an intermediate estimate of 46/(218-32) 24.7% 
(CI = 18530.9%). It is worth noting that the inter- 
mediate estimate obtained with the direct method is 
c 
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similar to that obtained with the indirect method, with 
comparable confidence intervals. However, the range 
of possible values remains wide with both methods. 
The investigators chose to report the following range 
of values around their point estimate of 25.7% (upper 
and lower limits of the 95% CI obtained by the direct 
method, 18.8-32.5%) [ 121. 
The direct method was also applied to the European 
Collaborative Study (ECS) dataset (N = 720 children 
born to HlV-seropositive mothers) using the 1987 
Centers for Disease Control case definition of paedi- 
atric AIDS [39]. A cur-off point of 18 months was cho- 
sen for the interpretation of the positive WB results. 
The direct method yielded an intermediate estimate 
of TR of 12.2% (CI = 9.8-14.5%). This range of val- 
ues includes the transmission rate of 14.4% reported 
by these investigators using more sophisticated clini- 
cal and laboratory criteria [25]. The indirect method 
could not be applied in this study, which did not have 
a comparison group. 
Application of the direct and indirect methods to other 
African data sets gave preliminary results in the range 
of 24% for the Uganda study [14] to 32% for the 
Malawi study (data not shown). i.e., comparable to 
the Kigali figures and twice the ECS intermediate es- 
timate. Table 5 summarizes the different estimates of 
the transmission rate obtained with three datasets. 
Looking at the intermediate estimates, one can see 
a substantial difference between the African studies 
and the European study which cannot be attributed 
to differences in methodology and sample size. 
Table 5. Range of possible values for the mother-to-child transmission 
rate CrR) of HIV-1 using two methods of calculation proposed by the 
Working Group on Mother-to-Child Transmission of HIV. Ghent, 1992. 
Kigali, Yampala and European Collaborative Study (ECS) datasets. 
Minimum Intermediate Maximum 
Study TR(%) (s.d.*) (s.d.*) (s.d.*) 
Kigali IM - .  25.7% (3.51%) - 
Kampala IM - 26.5% (2.51%) - 
ECS DM io.ovQ (i.iv0) 1 2 . 2 ~ ~  ( 1 . 2 ~  2a.3~/~ ( i . 7 ~  
DM 21.1~/~ ~ . 7 5 % )  2 4 . 7 ~ ~  ( 3 . 1 ~ ~ )  35.8~1~ e..27vO) 
DM 18.7% (1.94%) 24.2Oh (2.43%) 41.5% (2.46%) 
IM. indirect method; DM, direct method (see text for definitions). s.d., stan- 
dard deviation. 
Proposed scheme for data analysis 
For the purpose of comparing MTCT rates between 
studies, the direct method should be applied and re- 
sults presented with three estimates, each with their 
95% CI. For the purpose of internal validation of the 
measurement of the MTCT rate with several meth- 
ods in the same dataset, the indirect method should 
also be applied if an adequate comparison group is 
available and results presented with a 95% CI. Both 
methods should be applied to those groups of chil- 
dren born at least 15 months before the date of anal- 
ysis. This scheme for data analysis can also be applied 
to MTCT of HIV-2, which has been much less studied 
until now [40]. 
Determinants of mother-to-child transmission of 
HIV-1 
Before maternal risk factors for HIV MTCT can be 
assessed, it is necessary to ensure that the overall esti- 
mate of MTCT rate for a particular cohort is reliable, as 
well as the case-by-case classification of children born 
to HIV-seropositive mothers according to their prob- 
able HIV infection status. For example, a high loss to 
follow-up could invalidate these results. Few studies 
in developing countries have included the determina- 
tion of risk factors for MTCT as a specific objective 
[41]. Specifically designed studies with systematic and 
comprehensive data collection in pregnancy, at de- 
livery and in the post-partum period are therefore a 
priority, with strict enrollment criteria and follow-up 
procedures designed to minimize loss to follow-up. 
Finally, the workshop participants recognized the dif- 
ficulty in determining the exact role of each possible 
factor during data analysis - confounder, effect mod- 
ifier, marker or true risk factor. Furthermore, the tim- 
ing, route(s) and cellular mechanisms by which trans- 
mission occurs remained fundamental questions to be 
answered [42,43]. 
Factors that have been identified as possible risk fac- 
tors for HIV MTCT include impaired maternal clinical 
and immunological status [9,11,25], HIV-seroconver- 
sion during pregnancy [26], shortened duration of 
pregnancy [ 9,18,44], choriamnionitis [ 91, vaginal de- 
livery [21], prolonged and/or complicated labour E251 
and breast-feeding [45]. Maternal age and parity do 
not appear to be associated with MTCT in most stud- 
ies. In Rwanda [lí?], Kenya [ 161 and Malawi [ 171, sex- 
ually transmitted diseases were not associated with an 
increased risk of HIV MTCT. The role of other fac- 
tors, such as viral characteristics, protective maternal 
antibodies and genetic factors, ,is not yet clear [41]. 
In future, special consideration should be given to 
the relative importance of each mechanism of trans- 
mission and to the shidy of MTCT of HlV infection 
through breast-milk [45,46], in particular. Only four 
studies have included both breast- and formula-fed 
infants [9,21,23,25]. Three showed an increased trans- 
mission rate in breast-fed infants [9,23,25], However, 
the magnitude of the risk has not been described ac- 
curately and further studies are needed [ 45-48] . Their 
design should consider the nutritional and immuno- 
logical benefits of breast-milk. Post-natal transmission 
of HIV through breast-mik in women who serocon- 
verted after delivery has been demonstrated clearly 
[26] and highlights the importance of following-up 
HIV-seronegative mothers to observe maternal sero- 
conversion and possible subsequent post-natal trans- 
mission of HIV. . 
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